Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,168
  • Shares Outstanding, K 39,620
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -70 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.29
  • Price/Sales 48.61
  • Price/Cash Flow N/A
  • Price/Book 0.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.54 on 11/13/25
  • Next Earnings Date 06/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 477.35% (+81.50%)
  • Historical Volatility 78.18%
  • IV Percentile 98%
  • IV Rank 90.66%
  • IV High 518.95% on 11/20/25
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 15) 0.3400 (55.74%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 110
  • Volume Avg (30-Day) 763
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 17,070
  • Open Int (30-Day) 16,269
  • Expected Range 0.2700 to 0.9500

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.47
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +2.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4300 +40.70%
on 02/13/26
0.6538 -7.46%
on 03/04/26
+0.0788 (+14.98%)
since 02/04/26
3-Month
0.4300 +40.70%
on 02/13/26
4.6000 -86.85%
on 12/09/25
-3.6750 (-85.86%)
since 12/04/25
52-Week
0.4300 +40.70%
on 02/13/26
5.1400 -88.23%
on 11/24/25
-2.0450 (-77.17%)
since 03/04/25

Most Recent Stories

More News
UPCOMING DEADLINE: Vistagen Therapeutics, Inc. (VTGN) Securities Fraud Class Action - March 16, 2026 Lead Plaintiff Deadline

Vistagen Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights

VTGN : 0.6050 (-0.82%)
LEVI & KORSINSKY, LLP: TIMELINE OF ALLEGED MISREPRESENTATIONS IN VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION

DEADLINE: March 16, 2026

VTGN : 0.6050 (-0.82%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights - VTGN

NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit....

VTGN : 0.6050 (-0.82%)
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTGN

NEW YORK , March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).

VTGN : 0.6050 (-0.82%)
Vistagen to Participate in Upcoming Investor Conferences

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

VTGN : 0.6050 (-0.82%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics,...

VTGN : 0.6050 (-0.82%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , March 2, 2026 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN...

VTGN : 0.6050 (-0.82%)
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Vistagen To Contact Him Directly To Discuss Their Options

VTGN : 0.6050 (-0.82%)
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 27, 2026 /PRNewswire/ -- 

VTGN : 0.6050 (-0.82%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such...

VTGN : 0.6050 (-0.82%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.6863
2nd Resistance Point 0.6701
1st Resistance Point 0.6375
Last Price 0.6050
1st Support Level 0.5887
2nd Support Level 0.5725
3rd Support Level 0.5399

See More

52-Week High 5.1400
Fibonacci 61.8% 3.3408
Fibonacci 50% 2.7850
Fibonacci 38.2% 2.2292
Last Price 0.6050
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar